SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a major focus of community debate, with enthusiasts pushing for price catalysts and supply burns while skeptics share recurring fraud allegations and criticisms regarding the token's long-term utility. Despite the polarized sentiment, active traders are closely monitoring chart patterns for potential breakouts as they compare its performance against other meme coins.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant upward momentum driven by heavy institutional buying and intense speculative interest regarding a potential short squeeze, with investors closely watching the upcoming earnings report. The community is actively debating the stock's squeeze potential while highlighting the company's expanding enterprise voice AI partnerships as a major long-term catalyst.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The MELANIA token is trending as investors debate whether it represents a legitimate political engagement or yet another high-profile grift within the Trump-related crypto ecosystem. The community remains deeply polarized, with critics pointing to massive losses and historical pump-and-dump concerns, while a smaller cohort continues to speculate on future utility and market recovery.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is trending as investors weigh its aggressive pivot toward AI and high-performance computing infrastructure against concerns regarding capital expenditures, share dilution, and the absence of a long-awaited strategic AI partnership. While some community members remain bullish on the company's efficient mining operations and energy-linked assets, others are actively debating high short interest and management's capital allocation strategy ahead of upcoming earnings.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is gaining attention following the announcement of an End-of-Phase 2 meeting with the FDA, which cleared a registration path for its lead program, CAD-1005, to treat heparin-induced thrombocytopenia. Community discussion is split between optimism regarding the potential for this first-in-class 12-LOX inhibitor and skepticism driven by concerns over future capital raises and persistent bot-driven spam.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

FNMA is seeing a massive surge in volume and retail interest driven by high-profile endorsements from investors like Bill Ackman and Michael Burry, who are highlighting the stock as significantly undervalued. The community is actively debating the likelihood of a near-term IPO, potential conservatorship exit, and the influence of political rhetoric on the stock's future.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals is seeing increased market attention driven by anticipation surrounding near-term clinical readouts for its pipeline and continued commercial momentum from its existing portfolio. The investment community is actively debating the company's valuation, particularly the disconnect between its current revenue multiples and the potential upside of its liver disease treatments versus sector peers.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing intense community debate as investors speculate on the upcoming Goliath mainnet launch, with bulls pointing toward institutional adoption potential while bears remain skeptical of the project's long-term utility and historical price action. The conversation is currently dominated by conflicting perspectives on whether the coin is positioned for a significant technical breakout or if the current momentum is merely another recurring pump-and-dump cycle.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

Ghost is trending as traders debate its potential as a privacy-focused utility play on the Solana ecosystem versus concerns over project legitimacy and volatility. Community members are actively discussing upcoming infrastructure launches while navigating significant price swings and polarized opinions regarding its long-term viability.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as institutional interest peaks following news that Canada's AIMCO fund has acquired a significant stake in the company. Community members are actively debating the sustainability of Michael Saylor's leveraged Bitcoin accumulation strategy versus its potential for massive upside as the firm continues to grow its treasury holdings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prothena to Report First Quarter 2026 Financial Results on May 7

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...

Prothena (NASDAQ:PRTA) Shares Up 5.9% - Time to Buy?

Prothena (NASDAQ:PRTA) Trading Up 5.9% - Here's What Happened...

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter...

Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts

Shares of Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) have earned a consensus rating of "Hold" from the eleven analysts that are covering the company, Marketbeat.com reports. Two...

Prothena (NASDAQ:PRTA) Share Price Passes Above 200-Day Moving Average - Time to Sell?

Prothena (NASDAQ:PRTA) Share Price Passes Above 200 Day Moving Average - Here's Why...

Prothena Announces Leadership Team Updates

AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa

AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.

Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease

SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.

JPMorgan Chase & Co. Buys 608,814 Shares of Prothena Corporation plc $PRTA

JPMorgan Chase & Co. lifted its stake in shares of Prothena Corporation plc (NASDAQ:PRTA - Free Report) by 479.6% during the third quarter, according to the company in its most recent Form 13F filing...

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.35	--	--	N/A
Q4 '25	-$0.56	-$0.40	28.39%	BEAT
Q3 '25	-$0.69	-$0.68	1.04%	BEAT
Q2 '25	-$1.25	-$2.34	-86.64%	MISSED
Q1 '25	-$0.97	-$1.12	-15.46%	MISSED

PRTA
Prothena Corporation plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest PRTA News

PRTAProthena Corporation plc